Watch out, No­var­tis: Eli Lil­ly, Boehringer In­gel­heim notch broad heart fail­ure OK for Jar­diance

Eli Lil­ly and Boehringer In­gel­heim just got the green light to go much deep­er in­to the heart fail­ure mar­ket with their SGLT2 in­hibitor Jar­diance.

The FDA has ap­proved the drug as a treat­ment for a broad swath of pa­tients to re­duce their risk of car­dio­vas­cu­lar death and hos­pi­tal­iza­tion for heart fail­ure re­gard­less of ejec­tion frac­tion.

While Jar­diance was ini­tial­ly de­vel­oped and ap­proved for type 2 di­a­betes, Lil­ly and Boehringer have de­vised an ex­ten­sive clin­i­cal tri­al pro­gram to test its po­ten­tial in car­dio­vas­cu­lar dis­eases. Just six months ago, it was ap­proved for one type of heart fail­ure — with re­duced left ven­tric­u­lar ejec­tion frac­tion (LVEF).

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER